Physician
Saltzman, Tanis, Pittell, Levin and Jacobson
Saltzman, Tanis, Pittell, Levin and Jacobson was paid $201.29M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoSALTZMAN, TANIS, PITTELL, LEVIN AND JACOBSON
HOLLYWOOD, FL 33021
HOLLYWOOD, FL 33021
33aNPI1639138480assigned 03/21/2006
33bProvider typePediatrics Physician
28Total paid$201.29M
24GClaims19,123,619
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Florida
Rank by total paid#1 of 971
Median peer was paid$238K
This provider vs. median845×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 214,253 | $1.66M | |
| 2019 | 2,672,590 | $15.51M | |
| 2020 | 2,098,002 | $15.73M | |
| 2021 | 3,045,596 | $31.76M | |
| 2022 | 3,851,373 | $45.06M | |
| 2023 | 3,766,187 | $49.45M | |
| 2024incomplete | 3,475,618 | $42.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 1,735,588 | 1,656,290 | $46.43M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 988,981 | 945,646 | $40.67M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 15% | 510,821 | 500,059 | $29.81M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 13% | 441,996 | 406,946 | $25.80M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 10% | 368,346 | 361,473 | $20.91M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.0% | 203,497 | 199,532 | $12.12M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.0% | 1,016,064 | 991,334 | $8.14M |
| 99051 | 1.4% | 444,442 | 430,726 | $2.78M | |
| 90670 | 1.1% | 221,020 | 214,509 | $2.21M | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 5,867 | 5,322 | $845K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 4,522 | 3,974 | $591K |
| 99460 | <1% | 15,765 | 15,094 | $585K |
180 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 83,758 | $568K |
| 90461 | <1% | 532,304 | $564K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 13,300 | $512K |
| 90686 | <1% | 247,640 | $507K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,833 | $464K |
| 97802 | <1% | 24,029 | $458K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 264,293 | $446K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,542 | $376K |
| 1160F | <1% | 1,999,182 | $343K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,635 | $335K |
| 83655 | <1% | 132,230 | $325K | |
| 2001F | <1% | 2,772,757 | $325K | |
| 99188 | <1% | 44,152 | $285K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 22,253 | $267K |
| 90716 | <1% | 124,210 | $246K | |
| 85018 | <1% | 332,785 | $218K | |
| 99381 | <1% | 3,839 | $213K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 4,661 | $209K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,177 | $189K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 64,051 | $185K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 13,627 | $177K |
| 36415 | Collection of venous blood by venipuncture | <1% | 207,182 | $169K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14,060 | $152K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28,485 | $149K |
| 90651 | <1% | 76,521 | $119K | |
| 3074F | <1% | 1,125,452 | $114K | |
| 99383 | <1% | 1,927 | $112K | |
| 99462 | <1% | 4,446 | $104K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,571 | $101K |
| 99401 | <1% | 5,099 | $94K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,650 | $93K |
| 3078F | <1% | 1,125,837 | $91K | |
| 93000 | <1% | 9,269 | $90K | |
| 94010 | <1% | 6,330 | $84K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,108 | $80K |
| 90707 | <1% | 119,536 | $72K | |
| 92558 | <1% | 14,573 | $71K | |
| 90633 | <1% | 139,758 | $70K | |
| 90697 | <1% | 45,869 | $68K | |
| 93325 | <1% | 3,148 | $66K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 952 | $60K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,176 | $59K |
| 90715 | <1% | 16,494 | $54K | |
| 99243 | <1% | 492 | $51K | |
| 3008F | <1% | 1,522,170 | $50K | |
| 92552 | <1% | 3,611 | $47K | |
| 93320 | <1% | 2,536 | $46K | |
| 92551 | <1% | 341,284 | $45K | |
| 97803 | <1% | 2,200 | $42K | |
| 31231 | <1% | 286 | $37K | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 3,408 | $36K |
| 90648 | <1% | 197,903 | $35K | |
| 69000 | <1% | 276 | $34K | |
| 90677 | <1% | 46,941 | $33K | |
| 90621 | <1% | 14,150 | $32K | |
| 96127 | <1% | 208,906 | $31K | |
| 69210 | <1% | 2,288 | $28K | |
| 90680 | <1% | 152,523 | $28K | |
| 99205 | Prolong outpt/office vis | <1% | 130 | $27K |
| 81003 | <1% | 27,254 | $27K | |
| 99382 | <1% | 466 | $25K | |
| 0071A | <1% | 1,120 | $25K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 398 | $24K |
| 90619 | <1% | 10,518 | $22K | |
| 90734 | <1% | 38,747 | $21K | |
| 99177 | <1% | 457,406 | $19K | |
| 99384 | <1% | 338 | $19K | |
| 90723 | <1% | 138,281 | $17K | |
| 93304 | <1% | 363 | $16K | |
| 0072A | <1% | 638 | $15K | |
| 90656 | <1% | 18,839 | $15K | |
| 99000 | <1% | 40,547 | $15K | |
| 0001A | <1% | 920 | $11K | |
| 90696 | <1% | 20,554 | $11K | |
| 0002A | <1% | 445 | $10K | |
| 90685 | <1% | 5,570 | $10K | |
| 41010 | <1% | 70 | $10K | |
| 99221 | <1% | 169 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,766 | $10K |
| 99490 | Ccm add 20min | <1% | 278 | $10K |
| 87081 | <1% | 19,550 | $9K | |
| 90688 | <1% | 9,045 | $8K | |
| 94760 | <1% | 21,319 | $8K | |
| 95012 | <1% | 1,757 | $8K | |
| 99223 | Prolong inpt eval add15 m | <1% | 39 | $8K |
| 69399 | <1% | 83 | $7K | |
| 80061 | Lipid panel | <1% | 1,217 | $7K |
| 90700 | <1% | 22,914 | $7K | |
| 91300 | <1% | 2,538 | $7K | |
| 82947 | <1% | 3,526 | $6K | |
| 30901 | <1% | 70 | $6K | |
| 94664 | <1% | 690 | $6K | |
| 96380 | <1% | 2,363 | $6K | |
| 92587 | <1% | 758 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 364 | $5K |
| 87634 | <1% | 182 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 459 | $5K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 54 | $4K |
| 90681 | <1% | 187 | $4K | |
| 82948 | <1% | 961 | $4K | |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 152 | $4K |
| 90660 | <1% | 370 | $4K | |
| 99441 | <1% | 528 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 890 | $3K |
| 99072 | <1% | 3,391 | $3K | |
| 93321 | <1% | 365 | $3K | |
| 99173 | <1% | 22,508 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 285 | $2K |
| 92567 | <1% | 196 | $2K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 45 | $2K |
| 94060 | <1% | 86 | $2K | |
| 90672 | <1% | 418 | $2K | |
| 82247 | <1% | 962 | $2K | |
| 93227 | <1% | 71 | $1K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 11,100 | $1K |
| 93307 | <1% | 42 | $1K | |
| 90698 | <1% | 2,454 | $1K | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 1,663 | $1K |
| S9451 | Exercise classes, non-physician provider, per session | <1% | 23,371 | $1K |
| 17110 | <1% | 13 | $988.43 | |
| 99442 | <1% | 111 | $744.68 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 234 | $707.28 |
| 90671 | <1% | 40 | $620.20 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 343 | $605.28 |
| 81025 | <1% | 442 | $542.46 | |
| 85651 | <1% | 161 | $497.95 | |
| 90620 | <1% | 288 | $496.44 | |
| 81002 | <1% | 310 | $460.77 | |
| 96160 | <1% | 13,849 | $456.09 | |
| 90474 | <1% | 57 | $456.00 | |
| 87807 | <1% | 91 | $454.83 | |
| 87428 | <1% | 29 | $408.24 | |
| 85014 | <1% | 519 | $382.32 | |
| 69209 | <1% | 39 | $381.48 | |
| 69200 | <1% | 13 | $322.84 | |
| 90480 | <1% | 77 | $301.54 | |
| 82465 | <1% | 338 | $233.28 | |
| 77072 | <1% | 25 | $198.19 | |
| 98960 | <1% | 20 | $99.26 | |
| 93225 | <1% | 16 | $98.20 | |
| 36416 | <1% | 15,525 | $90.70 | |
| G9920 | Screening performed and negative | <1% | 3,754 | $59.00 |
| 90744 | <1% | 327 | $58.78 | |
| 74018 | <1% | 13 | $45.36 | |
| 99406 | <1% | 29 | $42.90 | |
| 90713 | <1% | 215 | $42.54 | |
| 81000 | <1% | 32 | $38.64 | |
| 90647 | <1% | 461 | $35.25 | |
| 99172 | <1% | 103 | $34.10 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 373 | $33.05 |
| 90649 | <1% | 49 | $28.36 | |
| 82962 | <1% | 13 | $26.66 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 592 | $19.98 |
| 3210F | <1% | 648 | $14.18 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 154 | $14.18 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 50 | $12.98 |
| 90380 | <1% | 124 | $5.00 | |
| A9150 | Non-prescription drugs | <1% | 150 | $0.04 |
| 91307 | <1% | 3,089 | $0.01 | |
| 91312 | 0% | 12 | $0.00 | |
| 4124F | 0% | 407 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 57 | $0.00 |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 35 | $0.00 |
| 90710 | 0% | 100 | $0.00 | |
| 4131F | 0% | 17 | $0.00 | |
| S9470 | Nutritional counseling, dietitian visit | 0% | 210 | $0.00 |
| 91308 | 0% | 39 | $0.00 | |
| 2010F | 0% | 5,185 | $0.00 | |
| 3079F | 0% | 1,350 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 202 | $0.00 |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 64 | $0.00 |
| 99174 | 0% | 559 | $0.00 | |
| 2030F | 0% | 13 | $0.00 | |
| 4056F | 0% | 13 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 36 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 83 | $0.00 |
| 1000F | 0% | 12 | $0.00 | |
| 90381 | 0% | 104 | $0.00 | |
| 91305 | 0% | 18 | $0.00 | |
| 4058F | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHULMAN, PETER (CHIEF EXECUTIVE OFFICE)
| Provider | Location | Paid |
|---|---|---|
| Pediatric Associates of Tampa Bay, LLC | Plantation, FL | $10.38M |
| Pediatric Associates of Northeast Florida, LLC | Plantation, FL | $7.74M |
| Saltzman, Tanis, Pittell, Levin and Jacobson, LLC | Hialeah, FL | $48K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.